Orzeyful (oveporexton)

Where it stands

According to the official records, the FDA approved Orzeyful (oveporexton) in the US on 2026-08-05. The sponsor is listed as Takeda Pharms Usa, and the application number is NDA220860. The product is a tablet.

The records do not give the approved indication or a therapeutic area, so this analysis cannot say which patients the product is approved for, the dose, or the line of therapy. Those details are in the approved prescribing information, which is not part of these records.

The records contain no CHMP opinion date and no information on any EU or other non-US regulatory activity. The only data point is the US approval.

Regulatory pathway and designations

The records list two designations: New molecular entity (NME) and Priority review. An NME is an active ingredient that has not previously been approved by the FDA, either alone or in combination. The approval was filed as a new drug application (NDA), consistent with the NDA number given.

Priority review is an FDA review designation, not a statement about the product's benefit. It is granted when a product is judged to offer a significant improvement in the safety or effectiveness of treating, diagnosing or preventing a serious condition. It shortens the FDA's target review timeline compared with standard review. The records do not give the submission date, the goal date or the basis on which priority review was granted, so the actual review duration cannot be assessed.

The records do not mention other expedited programs, such as Breakthrough Therapy, Fast Track or Accelerated Approval. They also do not say whether the approval is conventional or conditional in any sense. None should be assumed.

Safety and pharmacovigilance

The records contain no safety information: no warnings, contraindications, adverse-event data, REMS, or postmarketing requirements. No safety conclusions can be drawn from them.

What to watch

The first priority is the approved label, meaning the indication, dosing, boxed warning (if any), and warnings and precautions. The FDA approval documents and review package would also show the evidence base and any postmarketing commitments. None of this is in the records.

For a new molecular entity, readers typically follow the commercial launch timing, any postmarketing studies or safety commitments the FDA specifies, and early pharmacovigilance signals once the product is in wider use. The records say nothing about any of these, so they are items to check rather than expectations.

For teams with EU interests, the records show no CHMP opinion or EU filing. Any European regulatory plans would have to be confirmed from other sources, such as the sponsor or the EMA.